Bookmark and Share
Terbutaline (CID 5403) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(8)
 
 
Inactive(78)
 
 
Inconclusive(21)
 
 
Unspecified(233)
 
 
Top Targets:
7TM GPCR Srsx(23)
 
 
 
 
7TM GPCR Srx(21)
 
 
 
p450(8)
 
 
Tryp SPc(4)
 
 
 
Pyr redox dim(4)
 
 
BioAssay Types:
Literature(124)
 
 
 
 
 
Confirmatory(67)
 
 
 
Screening(11)
 
 
BioActivity Types:
IC50(133)
 
 
 
 
Potency(66)
 
 
 
Kd(2)
 
 
EC50(1)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 333    Data Row: 340   Total Pages: 7   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103709193]
Kd 2.51Binding affinity to human adrenergic beta2 receptor [AID426242, Type: Literature]Beta-2 adrenergic receptor [gi:296439450]
View
2
[SID103709193]
EC50 3.16228Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr [AID606103, Type: Literature]Beta-2 adrenergic receptor [gi:296439450]
View
3
[SID103709193]
Kd 3.98Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA) [AID40694, Type: Literature]
View
4
[SID48414500]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results [AID1189, Type: other]
View
5
[SID48414500]
DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results [AID1208, Type: other]
View
6
[SID48416600]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
7
[SID85209330]
Ligands of bioamine (Class A) GPCRs [AID2062, Type: other]
View
8
[SID103709193]
Apparent binding affinity constant to beta-2 adrenergic receptor determined using [3H]DHA [AID40687, Type: Literature]Beta-2 adrenergic receptor [gi:2851541]
View
9
[SID103709193]
ED50 1.04e+06Compound was tested for effective dose required for 50% of maximum response in guinea pig trachea [AID76656, Type: Literature]
View
10
[SID103709193]
Intrinsic activity (n=5) in guinea pig trachea [AID77606, Type: Literature]
View
11
[SID103709193]
Intrinsic activity in guinea pig trachea [AID77607, Type: Literature]
View
12
[SID103709193]
Binding to POPC (palmitoyl-oleolyl-phosphatidyl-choline) liposomes using biosensor system [AID156089, Type: Literature]
View
13
[SID103709193]
Binding to POPC/GMI liposomes using biosensor system [AID156203, Type: Literature]
View
14
[SID103709193]
Change in Gibb's free energy at Low affinity beta-2-adrenoreceptor in the membranes of bovine skeletal muscle preparation [AID218845, Type: Literature]
View
15
[SID103709193]
Change in Gibb's free energy at High affinity beta2- adrenoceptor in Chang living cells. [AID218847, Type: Literature]
View
16
[SID103709193]
Change in Gibb's free energy at Low affinity beta-2-adrenoreceptor in the Chang living cells [AID218848, Type: Literature]
View
17
[SID103709193]
Fraction absorbed in human intestine after oral administration compound was measured [AID236268, Type: Literature]
View
18
[SID103709193]
Permeability Coefficient in 2/4/A1 cell model [AID236912, Type: Literature]
View
19
[SID103709193]
Permeability Coefficient in Caco-2 cell culture model [AID236913, Type: Literature]
View
20
[SID103709193]
Permeability Coefficient in hexadecane membranes model [AID236914, Type: Literature]
View
21
[SID103709193]
Percentage of mass balance in hexadecane membranes model [AID236916, Type: Literature]
View
22
[SID103709193]
Clearance in human [AID310711, Type: Literature]
View
23
[SID103709193]
Volume of distribution at steady state in human after iv administration [AID540209, Type: Literature]
View
24
[SID103709193]
Clearance in human after iv administration [AID540210, Type: Literature]
View
25
[SID103709193]
Fraction unbound in human after iv administration [AID540211, Type: Literature]
View
26
[SID103709193]
Mean residence time in human after iv administration [AID540212, Type: Literature]
View
27
[SID103709193]
Half life in human after iv administration [AID540213, Type: Literature]
View
28
[SID103709193]
Drug absorption in human assessed as human intestinal absorption rate [AID567091, Type: Literature]
View
29
[SID103709193]
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans [AID588211, Type: Literature]
View
30
[SID103709193]
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents [AID588212, Type: Literature]
View
31
[SID103709193]
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents [AID588213, Type: Literature]
View
32
[SID103709193]
Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset [AID588220, Type: Literature]
View
33
[SID103709193]
Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis [AID592681, Type: Literature]
View
34
[SID103709193]
Apparent permeability of the compound by PAMPA [AID592684, Type: Literature]
View
35
[SID103709193]
Lipophilicity, log D of the compound [AID453203, Type: Literature]
View
36
[SID103709193]
Permeability in human skin after 48 hrs by Franz cell permeability assay [AID453204, Type: Literature]
View
37
[SID103709193]
Permeability across human Caco-2 cells [AID455986, Type: Literature]
View
38
[SID103709193]
Human intestinal absorption in po dosed human [AID476929, Type: Literature]
View
39
[SID103709193]
Absolute bioavailability in human [AID481439, Type: Literature]
View
40
[SID103709193]
Dissociation constant, pKa of the compound [AID481440, Type: Literature]
View
41
[SID103709193]
Aqueous diffusivity at 37C [AID481441, Type: Literature]
View
42
[SID103709193]
Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells [AID481442, Type: Literature]
View
43
[SID103709193]
Octanol-water partition coefficient, log P of the compound [AID481444, Type: Literature]
View
44
[SID103709193]
Effective permeability across human jejunum [AID481446, Type: Literature]
View
45
[SID103709193]
IC50 DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) [AID625193, Type: other]Acetylcholinesterase [gi:113037]
View
46
[SID103709193]
IC50 DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625151, Type: other]Muscarinic acetylcholine receptor M1 [gi:113118]
View
47
[SID103709193]
IC50 DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625152, Type: other]Muscarinic acetylcholine receptor M2 [gi:113122]
View
48
[SID103709193]
IC50 DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) [AID625153, Type: other]Muscarinic acetylcholine receptor M3 [gi:113125]
View
49
[SID103709193]
IC50 DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) [AID625228, Type: other]Androgen receptor [gi:113832]
View
50
[SID103709193]
IC50 DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) [AID625150, Type: other]Amine oxidase [flavin-containing] A [gi:113978]
View